UB Distinguished Professor Emeritus of Pharmaceutical Sciences Gerhard Levy was a pioneer and leading contributor in the areas of pharmacokinetics and clinical pharmacokinetics.
Levy is considered the originator of the biopharmaceutics field and the “father” of pharmacodynamics.
When Dr. Gerhard Levy retired in 2000 after four decades of service, the UB Department of Pharmaceutical Sciences established the lectureship, as well as a named seminar room, in recognition of the significant contributions Levy made in his fields of study and to honor a beloved friend and esteemed colleague who deftly balanced his love of teaching with robust research.
Can We Abandon the p-value?
Monday, October 22, 2018
190 Kapoor Hall, University at Buffalo South Campus
Carl C. Peck, MD
Adjunct Professor, Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco
Center for Drug Development Science, UC-Washington, Washington, DC
Chairman and Co-Founder, NDA Partners, LLC
Peck obtained a BA in mathematics and chemistry from the University of Kansas in 1963, and an MD in 1968. Following training in internal medicine, he undertook a research fellowship in clinical pharmacology at the University of California San Francisco (1972-74). From 1974 to 1980, Peck was employed at the Letterman Army Institute of Research in San Francisco. In 1980, he became Director of the Division of Clinical Pharmacology and Professor, Departments of Medicine and Pharmacology, Uniformed Services University, Bethesda, MD. He joined the FDA as Director, Center for Drug Evaluation and Research, in Oct 1987 and was promoted to Assistant Surgeon General in the Public Health Service in Oct 1990.
Retiring from FDA in late 1993, Peck was appointed “Boerhaave” Professor of Clinical Drug Research at Leiden University in The Netherlands. In 1994, Peck joined the faculty of the Georgetown University Medical Center, as the founding Director of the Center for Drug Development Science (CDDS). In 1999, he received the FDA Distinguished Alumnus Award. Sweden’s University of Uppsala conferred the Doctor Honoris Causa to Peck in Jan 2002 in recognition of "outstanding contributions to the science of drug development". He founded NDA Partners LLC in 2003 and in 2004, CDDS moved to UCSF. Peck received the 2012 ASCPT Gary Neal Prize for Innovation in Drug Development and the 2017 Sheiner-Beal Pharmacometrics Award.
His research interests center on optimizing informativeness, efficiency, speed and economy of drug development and regulation using advanced concepts and techniques of clinical pharmacology, trial designs, and pharmaco-statistical modeling and simulation to generate causal evidence of effectiveness and safety. Peck has mentored more than 40 postdoctoral fellows and graduate students and authored over 150 research papers, chapters and books.